Treatment of Dry Eye Disease with Autologous Platelet-Rich Plasma: A Prospective, Interventional, Non-Randomized Study

The definition of dry eye disease (DED), updated in 2007 by the International Dry Eye Workshop, is a multifactorial disease of the ocular surface and tears that produce symptoms of discomfort, visual disturbance, and tear film instability with potential damage to the ocular surface. It is accompanied by increased osmolarity of the tear film and inflammation of the ocular surface [1].

The prevalence of dry eye reported in the literature varies from 4% to 30% [2‐4]. Such wide discrepancies in the data may result from racial differences, different definitions, and the variety of tests used to determine DED. There are two main mechanisms that explain this ocular surface dysfunction: aqueous deficiency and excessive evaporation of the tear film. The aqueous deficient dry eye disease (ADDED) is characterized by an insufficient volume of tears due to dysfunction of the lacrimal glands and obstruction of the lacrimal ducts. This mechanism is also related to autoimmune diseases such as Sjögren’s syndrome, lupus, and rheumatoid arthritis. Meibomian gland dysfunction, eyelid problems (infrequent blinking, entropion, ectropion) are typical causes of evaporative dry eye. Poor tear film quality is the result of tear hyperosmolarity and goblet cell mucin deficiency [5].

The main standard treatment for dry eye is topical administration of artificial tears, although the expected results are not optimal and often ineffective. This has led to the use of other therapeutic strategies based on hemoderivatives. Autologous serum (AS) has been suggested as a more adequate treatment for severe DED over preservative-free artificial molecules, with variable success rates [6, 7]. Platelet rich plasma (PRP) and plasma rich in growth factors (PRGF) have also been reported as successful treatments for moderate to severe dry eye, presenting advantages over AS due to its richer concentration of growth factors, anti-inflammatory cytokines, and other platelet derivatives, which could be beneficial for the required ocular surface restoration in moderate to severe forms of dry eye [5, 8].

Autologous PRP is a hemoderivative with a high concentration of platelets obtained through a relatively simple process, which requires minimal manipulation and no addition of any other particular substance [9]. A recent study has shown that these components help in the proliferation, migration, and differentiation of corneal epithelial cells [10]. We have previously reported the outcomes of a pilot investigation with successful use of autologous PRP in the treatment of symptomatic dry eye [5].

The present study is a large non-randomised consecutive series of cases, conducted to evaluate prospectively the efficacy of topical administration of autologous PRP as monotherapy for the treatment of symptoms and clinical signs in cases affected by moderate to severe forms of chronic DED.

Prospective, interventional, non-randomized study conducted at the VISSUM Ophthalmology Institute in Alicante, Spain. Ethical committee approval was obtained for the purpose of this prospective investigation. The study followed the tenets of the Declaration of Helsinki [11], and adequate informed consent was obtained from all patients included in the study.

Adult patients with moderate to severe chronic DED (for 6 months or more)—according to the Dry Eye severity grading scheme proposed by the Dry Eye WorkShop (DEWS) [1] and Baudouin et al. [12]—were included in the study. This scheme takes into account the following parameters: ocular discomfort, visual symptoms, conjunctival injection, conjunctival and corneal fluorescein staining (CFS), corneal/tear signs, lid/meibomian glands, tear film break-up time (TBUT), and Schirmer test score [1].

Patients with previous ocular refractive surgery (LASIK, LASEK, or PRK), inability to attend the 6th week follow-up visit and patients who did not complete the follow-up protocol were excluded.

Any topical medication used formerly by the patient for the treatment of the DED was stopped 48 h before starting PRP treatment. Treatment consisted of monotherapy with PRP eye drops used on both eyes, one drop six times per day for at least 6 consecutive weeks (one round). When the improvement was initially poor or not satisfactory enough, some patients needed more than one round of PRP treatment.

Treatment response was evaluated by the results of the subjective questionnaires, the slit lamp examination and BCVA.

THree hundred and sixty-eight patients with DED were included in this study. Seventy-one patients were men (19.3%), and 297 patients were women (80.7%) with ages ranging from 18 to 77 years (mean 50.1 ± 15.8) and 18 to 89 years (mean 56.1 ± 16.6), respectively.

Before treatment with PRP, 121 patients (32.9%) received topical anti-inflammatory therapy for DED without beneficial results. Also, 19 subjects (5.2%) had been treated with autologous serum eye drops without noticing any improvement.

Two hundred and thirty-two patients (63%) had evaporative DED (EDED), while 136 patients (37%) had aqueous deficient DED (ADDED). Of the ADDED patients, 23 (16.9%) had Sjögren’s syndrome dry eye, while 113 (83.1%) had non-Sjögren’s ADDED.

Mean values of blood cell count before and after PRP preparation are shown in Table 1. The platelets count in the PRP samples was significantly higher than baseline value in the whole blood (p < 0.05), and the concentration index was 1.71. Red blood cells and leukocytes in the PRP decreased significantly after preparation, 99.5% and 81.2%, respectively (p < 0.05).

The Schirmer’s test value in the evaporative DED patients improved from 9.5 ± 3.6 mm to 13.8 ± 8.7 after the treatment (p < 0.05), and in the ADDED patients from 4.7 ± 2.7 to 6.4 ± 2.4 (p < 0.05).

Mean decimal BCVA of all subjects improved from 0.75 ± 0.3 at baseline to 0.82 ± 0.2 after the treatment with PRP. Globally these values were not statistically significant. One hundred and six patients (28.8%) experienced an improvement of one or more lines of vision. No improvement in vision was observed in 246 (66.9%) patients, while 16 (4.3%) patients lost one line of vision. The gain in lines of vision was significantly correlated with the improvement in the CFS score (p = 0.04, r = 0.61). Outcome results in each group are presented in Table 2.

Eight (2.2%) patients presented corneal ulcer due to severe dry eye before treatment with PRP. The associated pathologies in these subjects were thyroid eye disease, exposure keratopathy, uncontrolled cicatricial pemphigoid, graft versus host disease (GVHD), corneal leucomas (2), and severe non-Sjögren ADDED (2). They used two to three rounds of treatment with PRP, except for the patient with GVHD who needed up to five rounds. All of them had significant improvement in CFS parameters although they continued complaining of dry eye symptoms. Only one patient (0.02%) reported intolerance to the use of PRP eye drops due to extreme discomfort and stinging sensation at the time of instillation.

Regarding the number of rounds of PRP treatment, of the 368 patients treated, 237 (64.4%) received only one round of PRP (6 weeks consecutively) and 131 (35.6%) between two and five rounds. More ADDED patients used three cycles of PRP (p < 0.05), while no statistically significant difference was found between EDED and ADDED groups for other numbers of rounds. More patients with EDED (64.9%) used only one round of PRP in comparison with ADDED (55.9%), but this difference was not statistically significant. More rounds of PRP produced greater improvement in the subjective symptoms in ADDED (r = 0.64) than in EDED (r = 0.39) patients, while in terms of CFS, two or more cycles of PRP produced greater improvement in EDED (r = 0.62) than in ADDED (r = 0.51) patients, although these differences were not statistically significant (p > 0.05).

Dry eye disease comprehends a group of entities with an ocular surface disorder that can be caused by several factors and has different degrees of severity. Some patients experience mild symptoms that can be effectively treated with artificial tears, while others develop severe symptoms and complications of keratoconjunctivitis sicca such as infection, epithelial metaplasia, glandular dysfunction, and neurotrophic damage. The most frequently reported complaints of patients with dry eye syndrome are sandy-gritty eye irritation, burning, intermittent sharp pain, and photophobia, but often there is no association between the signs and symptoms of DED [15]. DED can also affect visual acuity due to tear film instability and induction of corneal irregularity.

At present, the first line of therapy for DED are artificial tears, which provide symptomatic relief by maintaining the ocular surface moistened, but do not resolve underlying causes. Other disadvantages include the need for frequent drop application and lower efficacy after long standing treatment. In more severe cases, anti-inflammatory therapy such as topical corticosteroids or cyclosporine A are used to improve signs and symptoms of DED [16]. An alternative approach in the treatment of moderate to severe dry eye disease is the use of autologous serum (AS). First described by Fox et al. [17] and later by Tsubota et al. [18], AS drops at 20% concentration have been shown to be an effective therapy for dry eye with Sjögren’s syndrome. However, in a comparative study conducted by Tananuvat et al. [19], no significant advantage in terms of tear film stability was found in the use of AS over artificial tears. Urzua et al. [7] also did not find superiority of AS over artificial tears in the treatment of dry eye in terms of tear film break-up time (BUT), Schirmer’s test or fluorescein staining. As advantages over artificial tears, AS is preservative-free and presents greater similarity to the natural healthy tear film in terms of pH, osmolarity, and biomechanical properties [20]. This blood-derived product contains vitamins and fibronectin which have epitheliotropic effects and help to maintain ocular surface’s integrity. However, AS is very poor in growth factors since platelets are eliminated in the process of its production [6]. In addition, there are many inconsistencies in AS’s methods of preparation, dilution, and storage, as well as uncertainty regarding their optimal concentration.

As a new alternative, plasma rich in growth factors (PRGF) is a hemoderivative product, which is different from AS, and has been proposed for the treatment of DED [8]. An experimental study showed that PRGF exerts more potent proliferative and anti-inflammatory effects than AS on a cell culture inflammatory model [21], although there is not any clinical research in humans comparing both blood products. Similar to PRGF, autologous PRP has been proposed for the treatment of dry eye syndrome with some theoretical advantages. Autologous PRP is a preservative-free biological product from the patient’s own blood and due to the presence of platelets and many biological active agents, PRP assists in the healing process. Autologous PRP has been successfully implemented in ophthalmology [9, 22] and can be stored at −20 °C for up to 3 months maintaining constant or slight variations in the concentration of the most important growth factors [23].

In the present report, we have undertaken a prospective investigation in a large scale basis to provide evidence of its effectiveness in the treatment of DED. We included 368 subjects and we show the beneficial effects of autologous PRP as monotherapy in the treatment of patients with DED. This hemoderivative product was well tolerated and almost no adverse effects (only 1.4%) were observed during the clinical study. PRP showed a considerable effect on relieving the signs and symptoms of DED. Similar results were obtained with PRGF when it was used in the treatment of evaporative dry eye, although that study included only 83 patients [24].

Regarding the 16 subjects who lost lines of vision after treatment, these were patients who suffered from pemphigoid cicatricial, GVHD, limbal stem cell deficiency (LSCD), caustication, or leucomas. Possibly this loss in CDVA was due to the progress of their underlying disease since most of them had improved subjective symptoms and CFS score.

Therefore, autologous PRP eye drops seems to be an attractive alternative option for the treatment of both evaporative and aqueous deficient DED, including Sjögren and non-Sjögren’s syndrome patients.

Significant advantages are cost effectiveness, ease of preparation and the autologous origin. The effectiveness of PRP is determined by the presence of platelets, growth factors and cytokines which are involved in proliferation, migration and differentiation of corneal epithelial cells, thus helping to maintain a proper condition of the ocular surface. Moreover, autologous PRP has been used successfully in other ocular surface disorders such as post-LASIK ocular surface syndrome, persistent epithelial defects, alkali burn, dormant ulcers, and corneal surface reconstructions in corneal perforations [25‐29].

This study has some limitations regarding its design. This work is not a randomized and controlled trial. Further investigations to assess the role of this therapeutic approach in the treatment of DED versus commercial artificial tear eyedrops or other hemoderivatives are necessary to determine the best approach in the management of moderate to severe forms of this frequent ocular surface disease.

Monotherapy with autologous PRP eye drops has shown to be a very good option for the treatment of moderate to severe chronic DED. Significant advantages are ease of preparation, absence of preservatives, its autologous origin, safety, and minimal or no intolerance.